KTRA (Kintara Therapeutics) Other Operating Expense : $-0.00 Mil (TTM As of Jun. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Kintara Therapeutics Other Operating Expense?

Kintara Therapeutics's Other Operating Expense for the three months ended in Jun. 2024 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.00 Mil.

Kintara Therapeutics's quarterly Other Operating Expense declined from Dec. 2023 ($-0.00 Mil) to Mar. 2024 ($-0.00 Mil) but then increased from Mar. 2024 ($-0.00 Mil) to Jun. 2024 ($0.00 Mil).

Kintara Therapeutics's annual Other Operating Expense increased from Jun. 2022 ($-0.00 Mil) to Jun. 2023 ($-0.00 Mil) and increased from Jun. 2023 ($-0.00 Mil) to Jun. 2024 ($0.00 Mil).

Kintara Therapeutics Other Operating Expense Historical Data

The historical data trend for Kintara Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics Other Operating Expense Chart

Kintara Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Other Operating Expense

Get a 7-Day Free Trial

Kintara Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Other Operating Expense	Get a 7-Day Free Trial															-	-	-	-	-

Kintara Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

Kintara Therapeutics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (NAS:KTRA) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

9920 Pacific Heights Boulevard, Suite 150, San Diego, CA, USA, 92121

Website

https://www.kintara.com

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Executives

Robert Hoffman	director, officer: President and CEO	ARENA PHARMACEUTICALS INC, 6166 NANCY RIDER DRIVE, SAN DIEGO CA 92121
Anthony Scott Praill	officer: Chief Financial Officer	2001-889 HOMER STREET, VANCOUVER A1 V6B 5S3
Saiid Zarrabian	director, officer: Head of Strategic Partnerships	P.O. BOX 675765, RANCHO SANTA FE CA 92067
Laura L. Johnson	director	C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Tamara A Seymour	director	C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Toth Robert Joseph Jr	director	543 LOMBARD ST, SAN FRANCISCO CA 94133
Dennis M Brown	officer: Chief Scientific Officer	100 SAN MATEO DR, MENLO PARK CA 94025
Keith Murphy	director	6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
John Liatos	director, officer: SVP, Business Development	12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
John K Bell	director	38 FALLBROOK LANE RR 33, CAMBRIDGE A6 N3H 4R8
Napoleone Ferrara	director	550 FRONT STREET, UNIT 1103, SAN DIEGO CA 92101
Lynda Sarah Cranston	director	4316 LOCARNO CRESCENT, VANCOUVER A1 V6R 1G3
Erich Mohr	director	8300 GREENSBORO DRIVE, MCLEAN VA 22102
Jeffrey Bacha	director	SUITE 3 1545 WEST 14TH AVENUE, VANCOUVER A1 V6J 2J1
William J Garner	director	875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010